Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
36.77
+0.25 (0.68%)
At close: Aug 14, 2026, 4:00 PM EDT
36.75
-0.02 (-0.05%)
After-hours: Aug 14, 2026, 7:50 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Teva Pharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $41.4. The average 1-year stock price forecast is 12.59% higher than the current stock price, while the lowest is $33 (-10.25%) and the highest is $50 (+35.98%).
Price Target: $41.4 (+12.59%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Teva Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 7 | 7 | 7 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $40 → $42 | Buy | Maintains | $40 → $42 | +14.22% | Aug 12, 2026 |
| UBS | UBS | Buy Maintains $42 | Buy | Maintains | $42 | +14.22% | Aug 7, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $40 → $41 | Buy | Reiterates | $40 → $41 | +11.50% | Jul 30, 2026 |
| Scotiabank | Scotiabank | Buy Maintains $40 | Buy | Maintains | $40 | +8.78% | Jul 30, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $42 → $44 | Buy | Reiterates | $42 → $44 | +19.66% | Jul 28, 2026 |
Financial Forecast
Revenue This Year
16.58B
from 17.26B
Decreased by -3.92%
Revenue Next Year
17.30B
from 16.58B
Increased by 4.36%
EPS This Year
n/a
EPS Next Year
n/a